A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
← catalyst calendarNCT07391761 · readout in 530 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1estimated
Sites
4
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-11 | actual | When the study began enrolling |
| Primary completion | 2028-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Refractory Multiple Myeloma (RRMM)
Intervention
- Drug: Non intervention
Primary outcomes
what the primary-completion date above is the date OFrwTTR (real-world time to response)
measured At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)
rwORR (real-world overall response rate)
measured At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)
rwDOR (real-world duration of response）
measured From first response until 18 months
rwPFS (real-world progression-free survival)
measured From initiation of elranatamab treatment (index date) until 18 months
rwOS (real world overall survival)
measured From initiation of elranatamab treatment (index date) until 18 months
rwTTNT (real world time to next treatment)
measured From initiation of elranatamab treatment (index date) until 18 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed